MX2023005994A - Compositions of peptide inhibitors of interleukin-23 receptor. - Google Patents

Compositions of peptide inhibitors of interleukin-23 receptor.

Info

Publication number
MX2023005994A
MX2023005994A MX2023005994A MX2023005994A MX2023005994A MX 2023005994 A MX2023005994 A MX 2023005994A MX 2023005994 A MX2023005994 A MX 2023005994A MX 2023005994 A MX2023005994 A MX 2023005994A MX 2023005994 A MX2023005994 A MX 2023005994A
Authority
MX
Mexico
Prior art keywords
compositions
interleukin
receptor
peptide inhibitors
disorders
Prior art date
Application number
MX2023005994A
Other languages
Spanish (es)
Inventor
Mohammad Masjedizadeh
Xiaoli Cheng
Ashok Bhandari
Shu Li
Gopal Rajan
Anne M Fourie
Pretoro Giustino Di
Dajun Sun
Geraldine Broeckx
Nathalie Mertens
Felix Lai
Beverly M Knight
David Polidori
Santhosh Francis Neelamkavil
Nishit Modi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023005994A publication Critical patent/MX2023005994A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ceramic Engineering (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
MX2023005994A 2020-11-20 2021-11-19 Compositions of peptide inhibitors of interleukin-23 receptor. MX2023005994A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116568P 2020-11-20 2020-11-20
US202163275222P 2021-11-03 2021-11-03
PCT/US2021/060183 WO2022109328A1 (en) 2020-11-20 2021-11-19 Compositions of peptide inhibitors of interleukin-23 receptor

Publications (1)

Publication Number Publication Date
MX2023005994A true MX2023005994A (en) 2023-08-11

Family

ID=81708151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005994A MX2023005994A (en) 2020-11-20 2021-11-19 Compositions of peptide inhibitors of interleukin-23 receptor.

Country Status (15)

Country Link
US (1) US11939361B2 (en)
EP (1) EP4247403A1 (en)
JP (1) JP7397239B2 (en)
KR (1) KR20230110570A (en)
AU (1) AU2021383828A1 (en)
CA (1) CA3202226A1 (en)
CL (1) CL2023001417A1 (en)
CO (1) CO2023007172A2 (en)
DO (1) DOP2023000091A (en)
IL (1) IL302996A (en)
MX (1) MX2023005994A (en)
PE (1) PE20240631A1 (en)
TW (1) TW202237167A (en)
UY (1) UY39527A (en)
WO (1) WO2022109328A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211911T1 (en) 2013-03-15 2022-03-18 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
CN113621027A (en) 2014-05-16 2021-11-09 领导医疗有限公司 Thioether peptide antagonists of alpha 4 beta 7 integrins
RU2736637C9 (en) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN118005737A (en) 2020-01-15 2024-05-10 詹森生物科技公司 Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases
TW202237167A (en) 2020-11-20 2022-10-01 比利時商健生藥品公司 Compositions of peptide inhibitors of interleukin-23 receptor
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
JPH02306947A (en) 1989-05-01 1990-12-20 Monsanto Co Preparation of chiral bata-amino acid
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
EP0578728B1 (en) 1991-04-05 1998-07-01 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIIIa
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
DK0644772T3 (en) 1992-11-12 2003-06-30 Sod Conseils Rech Applic Opioid peptides
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
BRPI9711437B8 (en) 1996-08-30 2021-05-25 Novo Nordisk As glp-1 derivatives
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5993811A (en) 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
JP2001509493A (en) 1997-07-11 2001-07-24 インナーダイン， インコーポレイテッド Methods and systems for preparation and sealing of radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
EP1033983A1 (en) 1997-11-24 2000-09-13 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
JP2002524108A (en) 1998-07-28 2002-08-06 インナーダイン， インコーポレイテッド Absorbable brachytherapy and chemotherapy delivery devices and methods
JP2002522063A (en) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド Generation of modified molecules with increased serum half-life
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
BR0009040A (en) 1999-03-17 2001-12-18 Novo Nordisk As Method for acylating an amino group of a peptide or a protein, and, compound
EP1183254B1 (en) 1999-04-12 2005-01-12 Aventis Pharma Limited Substituted bicyclic heteroaryl compounds as integrin antagonists
AU2001262089A1 (en) 2000-03-14 2001-09-24 Novartis Ag Alpha4beta1 and alpha4beta7 integrin inhibitors
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1349574A2 (en) 2001-01-09 2003-10-08 MERCK PATENT GmbH Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
DE10107707A1 (en) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonists for alpha¶4¶beta¶7¶ integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
US20040176293A1 (en) 2002-12-18 2004-09-09 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
WO2004092405A2 (en) 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
PL1680443T3 (en) 2003-11-05 2014-02-28 Dana Farber Cancer Inst Inc Stabilized alpha helical peptides and uses thereof
WO2005064345A2 (en) 2003-12-19 2005-07-14 Applera Corporation Methods and systems for protein and peptide evidence assembly
EA012872B1 (en) 2004-01-09 2009-12-30 Пфайзер Инк. ANTIBODIES TO MAdCAM
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
WO2006000034A1 (en) 2004-06-24 2006-01-05 The Walter And Eliza Hall Institute Of Medical Research Conjugates and therapeutic uses thereof
JP5154935B2 (en) 2004-09-23 2013-02-27 ザ・ユニヴァーシティ・オブ・メルボーン Antigen complex for diagnosing and treating Porphyromonas gingivalis infection
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20080300180A1 (en) 2004-11-30 2008-12-04 Gastrotech Pharma A/S Growth Hormone Secretagogue Receptor 1A Ligands
US20100183617A1 (en) 2005-02-23 2010-07-22 University Of Virginia Patent Foundation Compositions and methods for regulating sas1r
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP2016177A2 (en) 2006-04-12 2009-01-21 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
RU2008150483A (en) 2006-05-22 2010-06-27 Клиникал Дженомикс Пти Лтд (Au) IDENTIFICATION METHOD
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US20080019913A1 (en) 2006-07-07 2008-01-24 University Of Arizona Office Of Technology Transfer Enkepahlin analogs with improved bioavailability
KR101399175B1 (en) 2006-07-21 2014-06-19 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 Anti-inflammatory and antiallergic cyclic peptides
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
WO2008140602A2 (en) 2006-12-07 2008-11-20 The Govenment Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN
JP2010517529A (en) 2007-02-02 2010-05-27 アムジエン・インコーポレーテツド Hepcidin and hepcidin antibody
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
TR201821029T4 (en) 2007-02-23 2019-01-21 Merck Sharp & Dohme Improved anti-IL-23p19 antibodies.
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2150564A2 (en) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2008144041A1 (en) 2007-05-21 2008-11-27 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
US20100190710A1 (en) 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CN101358201A (en) 2007-07-31 2009-02-04 钱忠明 Recombinant human iron-regulatory hormone adenovirus, preparation method and application thereof
CN101307085B (en) 2007-08-01 2012-06-13 香港理工大学深圳研究院 SiRNA and recombination lentivirus from preventing hepcidin from regulating protein and uses thereof
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
GR1006896B (en) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, A process for producing a peptide hormone.
WO2009039185A1 (en) 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
US20100280098A1 (en) 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
US20110212104A1 (en) 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
EP3208279B1 (en) 2008-12-05 2021-04-21 The Regents of The University of California Mini-hepcidin peptides and methods of using thereof
DE102009007381A1 (en) 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotic peptides
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
JP5669728B2 (en) 2009-04-08 2015-02-12 武田薬品工業株式会社 Neuromedin U derivative
TWI578992B (en) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 Hepcidin binding nucleic acids
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011091357A1 (en) 2010-01-25 2011-07-28 Cornell University Aromatic-cationic peptides and uses of same
US9523073B2 (en) 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
JP2011231085A (en) 2010-04-30 2011-11-17 Osaka Prefecture Univ Cyclic peptide
WO2011149942A2 (en) 2010-05-24 2011-12-01 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
IT1406051B1 (en) 2010-08-05 2014-02-06 D M G Italia S R L USE OF HMGB1 AS A BIOLOGICAL MARKER OF HUMAN INTESTINAL INFLAMMATION, A NON-INVASIVE METHOD FOR ITS DETECTION IN FECAL SAMPLES AND RELATIVE KIT.
LT2603232T (en) 2010-08-11 2020-01-27 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
WO2012101599A2 (en) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CA2839408A1 (en) 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
AU2012327226C1 (en) 2011-12-09 2017-03-02 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
US20150157692A1 (en) 2012-05-23 2015-06-11 The University Of Chicago Methods of treating obesity
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
JP2016508722A (en) 2013-02-15 2016-03-24 エスアールエックス カーディオ，エル エル シー PCSK9 (proprotein convertase subtilisin / kexin type 9) allosteric binding ligand to regulate serum low density lipoprotein (LDL) levels
HRP20211911T1 (en) 2013-03-15 2022-03-18 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
KR102247493B1 (en) 2013-06-24 2021-04-30 가부시키가이샤 캔버스 Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations
WO2014210056A1 (en) 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
JP2016534043A (en) 2013-10-09 2016-11-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for down-regulation of pro-inflammatory cytokines
WO2015112700A1 (en) 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
EP3129040A4 (en) 2014-04-07 2018-03-21 La Jolla Pharmaceutical Company Hepdicin mimetic peptides and uses thereof
CN113621027A (en) 2014-05-16 2021-11-09 领导医疗有限公司 Thioether peptide antagonists of alpha 4 beta 7 integrins
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
US20170313754A1 (en) 2014-06-27 2017-11-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses thereof
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
RU2736637C9 (en) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
EP3240799B1 (en) 2014-12-29 2021-03-31 The Regents of the University of California S-alkylated hepcidin peptides and methods of making and using thereof
US20160199437A1 (en) 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20160228491A1 (en) 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
WO2016195663A1 (en) 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
WO2016200364A1 (en) 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
MX2018000542A (en) * 2015-07-15 2018-06-27 Protagonist Therapeutics Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109195618A (en) 2016-03-23 2019-01-11 领导医疗有限公司 Method for synthesizing 4 β of α, 7 peptide antagonists
US20190264197A1 (en) 2016-07-27 2019-08-29 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
US20190270786A1 (en) 2016-07-27 2019-09-05 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US20200064357A1 (en) 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
US11192918B2 (en) 2016-12-06 2021-12-07 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
AU2018210174B2 (en) 2017-01-18 2022-04-07 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TW201920234A (en) 2017-09-11 2019-06-01 美商領導醫療有限公司 Opioid agonist peptides and uses thereof
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US20220257600A1 (en) 2018-06-20 2022-08-18 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
JOP20190150A1 (en) 2018-06-21 2019-12-21 Merck Sharp & Dohme Pcsk9 antagonist compounds
EP3820883A4 (en) 2018-07-12 2022-04-20 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3135024A1 (en) 2019-03-28 2020-10-01 Protagonist Therapeutics, Inc. Methods for synthesizing .beta.-homoamino acids
TW202116793A (en) 2019-07-10 2021-05-01 美商領導醫療有限公司 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021046246A1 (en) 2019-09-03 2021-03-11 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
JP2023509790A (en) 2020-01-10 2023-03-09 プロタゴニスト セラピューティクス， インコーポレイテッド Methods for treating inflammatory bowel disease with α4β7 integrin antagonists
CN118005737A (en) 2020-01-15 2024-05-10 詹森生物科技公司 Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases
CA3168135A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20230129095A1 (en) 2020-01-15 2023-04-27 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2023540679A (en) 2020-07-28 2023-09-26 プロタゴニスト セラピューティクス， インコーポレイテッド Conjugated hepcidin mimetics
TW202237167A (en) 2020-11-20 2022-10-01 比利時商健生藥品公司 Compositions of peptide inhibitors of interleukin-23 receptor
WO2022212698A1 (en) 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2022249095A1 (en) 2021-04-01 2023-10-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3214153A1 (en) 2021-04-01 2022-10-06 Gregory Thomas Bourne Conjugated hepcidin mimetics
KR20240021833A (en) 2021-06-14 2024-02-19 프로타고니스트 테라퓨틱스, 인코포레이티드 Hepcidin mimetics for the treatment of hereditary hemochromatosis
CA3226539A1 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor
TW202321275A (en) 2021-07-14 2023-06-01 美商健生生物科技公司 Bicyclic peptide inhibitors of interleukin-23 receptor
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Lipidated peptide inhibitors of interleukin-23 receptor

Also Published As

Publication number Publication date
CL2023001417A1 (en) 2023-12-15
JP7397239B2 (en) 2023-12-12
AU2021383828A1 (en) 2023-07-06
DOP2023000091A (en) 2023-12-29
KR20230110570A (en) 2023-07-24
PE20240631A1 (en) 2024-03-26
IL302996A (en) 2023-07-01
JP2023545212A (en) 2023-10-26
CO2023007172A2 (en) 2023-06-20
US11939361B2 (en) 2024-03-26
EP4247403A1 (en) 2023-09-27
TW202237167A (en) 2022-10-01
WO2022109328A1 (en) 2022-05-27
US20220177532A1 (en) 2022-06-09
UY39527A (en) 2022-06-30
CA3202226A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2023005994A (en) Compositions of peptide inhibitors of interleukin-23 receptor.
WO2023288019A3 (en) Lipidated peptide inhibitors of interleukin-23 receptor
MX2022008741A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
WO2023288017A3 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
MX2022008740A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
CR20210552A (en) Nlrp3 inflammasome inhibitors
MX2021000925A (en) Nlrp3 inflammasome inhibitors.
MX2022000397A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
SG10201810154WA (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
AR119389A1 (en) INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2022005232A (en) Small molecule degraders of helios and methods of use.
MX2020006459A (en) DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS.
WO2023288028A3 (en) Peptide inhibitors of interleukin-23 receptor
MX2022003671A (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease.
SA520411787B1 (en) Benzimidazole derivatives and their uses
EA202190153A1 (en) AXL / MER INHIBITOR COMPOSITIONS
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
MX2023003348A (en) Compounds and compositions as modulators of tlr signaling.
MX2020009566A (en) Compounds as modulators of tlr2 signaling.
MX2021011596A (en) Compounds and compositions as modulators of tlr signaling.
AU2018276273A1 (en) Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
MX2021008507A (en) Lilrb3-binding molecules and uses therefor.
MX2022005843A (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5.